AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)

Launched by TONGJI HOSPITAL · Jul 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new computer tool that uses artificial intelligence (AI) to predict if liver cancer (called hepatocellular carcinoma or HCC) might come back aggressively after surgery. The goal is to see if this AI can accurately identify patients who are at high risk of cancer returning within two years after having part of their liver removed. This could help doctors better plan care and follow-up for patients after surgery.

People who may join this study are adults aged 18 to 75 who have early-stage liver cancer and are scheduled for surgery to remove the cancer. Before surgery, they need to have a special type of MRI scan of their liver. Participants will have the usual surgery and then get regular imaging tests for two years to watch for any signs of the cancer returning. The information collected will help the researchers check how well the AI model works. Women who are pregnant or breastfeeding, people with other serious health problems, or those with different types of cancer are not eligible. This study is currently looking for volunteers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-75 years, regardless of gender.
• • BCLC stage 0-A, scheduled for curative liver resection.
• • Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
• • Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
• • Child-Pugh liver function score ≤7.
• • ECOG Performance Status (PS) 0-1.
• • No severe organic diseases of the heart, lungs, brain, or other vital organs.
• Exclusion Criteria:
• • Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).
• • Postoperative pathology confirms non-HCC diagnosis.
• • Pregnant or lactating women.
• • History of organ transplantation.
• • Inability to comply with the study protocol or follow-up schedule.